ArticleThe American journal of tropical medicine and hygiene2012
Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome.
Article in The American journal of tropical medicine and hygiene, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Treatment for Dientamoeba fragilis: A Systematic Review and Meta-analysis.Infectious diseases and therapy · 2026Pooled it
- The role of Blastocystis sp. and Dientamoeba fragilis in irritable bowel syndrome: a systematic review and meta-analysis.Parasitology research · 2017Pooled it
- Review
- Aspects of Genetic Diversity, Host Specificity and Public Health Significance of Single-Celled Intestinal Parasites Commonly Observed in Humans and Mostly Referred to as 'Non-Pathogenic'.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025Review
- A Cross-Sectional Study on the Occurrence of the Intestinal Protist,International journal of molecular sciences · 2022Article
- Gut Microbiota Shifting in Irritable Bowel Syndrome: The Mysterious Role ofFrontiers in medicine · 2022Review
- Distribution and relevance of Dientamoeba fragilis and Blastocystis species in gastroenteritis: results from a case-control study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Paromomycin is superior to metronidazole in Dientamoeba fragilis treatment.International journal for parasitology. Drugs and drug resistance · 2019Article
- No association between abdominal pain andArchives of disease in childhood · 2019Article
- Clinical and Epidemiological Characteristics of Patients withThe American journal of tropical medicine and hygiene · 2018Observational
- The Human Gut ColonizerFrontiers in cellular and infection microbiology · 2018Article
- Article
- Dientamoeba fragilis, the Neglected Trichomonad of the Human Bowel.Clinical microbiology reviews · 2016Review
- History of antimicrobial use and the risk of Dientamoeba fragilis infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015Article
- Understanding drug resistance in human intestinal protozoa.Parasitology research · 2015Review
- The relationship between intestinal parasites and some immune-mediated intestinal conditions.Gastroenterology and hepatology from bed to bench · 2015Review
- Molecular testing for clinical diagnosis and epidemiological investigations of intestinal parasitic infections.Clinical microbiology reviews · 2014Review
- Article
- Blastocystis: Genetic diversity and molecular methods for diagnosis and epidemiology.Tropical parasitology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of Dientamoeba fragilis in irritable bowel syndrome (IBS) is incompletely known. We aimed to investigate whether eradication of D. fragilis alleviates symptoms in IBS. Twenty-five D. fragilis-positive IBS patients were treated with Metronidazole (MZ) or Tetracycline. The patients were mostly female (89%), and mean age (SD) was 35.1 (8.2) years. Microbiological response, evaluated 2 weeks post-treatment, was observed in 15 of 25 patients (60%), all by MZ. Clinical response, defined as adequate relief of symptoms, was observed in 7 of 22 patients (32%), all by MZ. In a logistic regression analysis, we found no significant association between clinical and microbiological response. This case study did not support our hypothesis of a simple association between D. fragilis and IBS. Some D. fragilis-infections were insufficiently treated by MZ. Further studies into the prevalence and effect of eradication of D. fragilis in IBS and into efficient treatments of D. fragilis are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.